000087589 001__ 87589
000087589 005__ 20240111111737.0
000087589 0247_ $$2doi$$a10.1186/s12944-019-1153-x
000087589 0248_ $$2sideral$$a115794
000087589 037__ $$aART-2019-115794
000087589 041__ $$aeng
000087589 100__ $$0(orcid)0000-0002-1894-1621$$aPerez-Calahorra, S.$$uUniversidad de Zaragoza
000087589 245__ $$aComparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
000087589 260__ $$c2019
000087589 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087589 5203_ $$aBackground: There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Methods: This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if this occurred after 2005, and time of first event without date restriction. Results: Baseline characteristics were similar between treatment groups. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. At the inclusion of the subject in the registry, 345 participants had not suffered a recurrence yet. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively. There were no statistically significant differences between the two groups independently of the follow-up start-time. Conclusions: This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD.
000087589 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-ERDF/CIBERCV-CB16-11-00451
000087589 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000087589 590__ $$a2.906$$b2019
000087589 591__ $$aNUTRITION & DIETETICS$$b47 / 89 = 0.528$$c2019$$dQ3$$eT2
000087589 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b166 / 296 = 0.561$$c2019$$dQ3$$eT2
000087589 592__ $$a0.942$$b2019
000087589 593__ $$aBiochemistry (medical)$$c2019$$dQ1
000087589 593__ $$aClinical Biochemistry$$c2019$$dQ1
000087589 593__ $$aEndocrinology$$c2019$$dQ2
000087589 593__ $$aEndocrinology, Diabetes and Metabolism$$c2019$$dQ2
000087589 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000087589 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, M.
000087589 700__ $$aMarco-Benedi, V.
000087589 700__ $$aPinto, X.
000087589 700__ $$aSanchez-Hernandez, R.M.
000087589 700__ $$aPlana, N.
000087589 700__ $$aOrtega, E.
000087589 700__ $$aFuentes, F.
000087589 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000087589 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000087589 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000087589 773__ $$g18 (2019), 216 [6 pp.]$$pLipids health dis.$$tLipids in Health and Disease$$x1476-511X
000087589 8564_ $$s519158$$uhttps://zaguan.unizar.es/record/87589/files/texto_completo.pdf$$yVersión publicada
000087589 8564_ $$s102856$$uhttps://zaguan.unizar.es/record/87589/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000087589 909CO $$ooai:zaguan.unizar.es:87589$$particulos$$pdriver
000087589 951__ $$a2024-01-11-10:59:41
000087589 980__ $$aARTICLE